Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 3, 2016, Pages

  Majed, Masoud ^a   Fryer, James P ^a   McKeon, Andrew ^a   Lennon, Vanda A ^a,b   Pittock, Sean J ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; IMMUNOGLOBULIN G;

ANTIBODY DETECTION; ARTICLE; CASE STUDY; CELL ASSAY; CEREBROSPINAL FLUID; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENT CELL BASED ASSAY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84996870060     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000231     Document Type: Article

References (13)

1. Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann NY Acad Sci Epub 2015 Jun 10.
2. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
4. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010;298:158-162.
5. Fryer JP, Lennon VA, Pittock SJ, et al. AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm 2014;1:e11. doi: 10.1212/NXI.0000000000000011.
6. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-671; discussion 669.
7. Dujmovic I, Mader S, Schanda K, et al. Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders. J Neuroimmunol 2011;234:124-130.
8. Jarius S, Franciotta D, Paul F, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 2010;7:52.
9. Sato DK, Callegaro D, de Haidar Jorge FM, et al. Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks. Ann Neurol 2014;76:305-309.
10. Takahashi T, Fujihara K, Nakashima I, et al. Antiaquaporin- 4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130: 1235-1243.
11. McKeon A, Pittock SJ, Lennon VA. CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology 2011;76:1108-1110.
12. Reiber H, Lange P. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem 1991;37:1153-1160.
13. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014;13:167-177.